Roche and Mayo Clinic Collaborate on AmpliChip CYP450 Drug Selection Tool

A previous posting on the AmpliChip CYP450 test for individual variability in drug metabolism (one of Forbes' "top ten medical tests you need," oddly) is here. Via Reuters:

Roche Holding AG's diagnostics division and U.S.-based Mayo Clinic have agreed to investigate offering drug selection and dosing information for the treatment of psychiatric patients.

The companies' first step is to co-develop a prototype IT-enabled system that will refine Mayo Clinic's extensive psychiatric and pharmacogenomic clinical expertise, Roche said in a statement on Tuesday.

The prototype system will offer drug selection and dosing information for a broad range of psychotropic therapeutics based on patient test results from Roche's AmpliChip CYP450 test.

Technorati Tags: Roche, Mayo Clinic, AmpliChip, CYP450